-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The total prevalence of brain metastases from non-small cell lung cancer ( NSCLC ) is about 10%-20% at the initial visit, and as high as 40% during the entire medical visit, and the prognosis is poor.
The overall survival rate is about 3-6 months.
.
Therefore, the early detection and diagnosis of brain metastases are crucial to the choice of treatment options and prognosis of patients
The total prevalence of brain metastases from non-small cell lung cancer ( NSCLC ) is about 10%-20% at the initial visit, and as high as 40% during the entire medical visit, and the prognosis is poor.
The existing guidelines suggest that the brain MRI staging of stage I and stage II NSCLC is not consistent
Recently, a study published in the journal Radiology explored the value of brain MRI staging for early diagnosis of NSCLC patients, and provided a valuable reference for further optimizing the clinic and treatment process of NSCLC patients
A total of 1712 patients (mean age 64 years ± 10 [standard deviation]; 1035 males) were included in this study
.
The brain MRI staging diagnosis rate of newly diagnosed NSCLC was 11.
Diagnosis of adenocarcinoma than squamous cell carcinoma , EGFR mutation positive diagnosis of adenocarcinoma of EGFR mutation-negative adenocarcinoma
Table of brain MRI staging diagnosis rate and false referral rate by clinical staging group
.
.
Figure 60-year-old female, clinical stage IB group, positive epidermal growth factor receptor mutation with brain metastasis
.
(a, b) The chest CT enhanced image showed a 3.
Figure 60-year-old female, clinical stage IB group, positive epidermal growth factor receptor mutation with brain metastasis
In summary, brain MRI staging has a low diagnostic rate for clinical staging of patients with non-small cell lung cancer
Original source:
Minjae Kim , Chong Hyun Suh , Sang Min Lee , et al.
Kim Minjae , Chong Hyun Suh , Sang Min Lee , et Al.
The Diagnostic Yield of the MRI Brain Staging in Newly Diagnosed Patients with the Cell Lung Cancer Non-the Small .
The DOI: 10.
1148 / radiol.
2020201194 10.
1148 / radiol.
2020201194 in this message
